Another 2 cents worth.
There is defnitely no return of the license. The way I understand it that, ABT still retains semi-exclusive rights on the automated test (only the manual tests are exempt). So they are still very much a potential distribution channel and would like to limit the number of licensees with automated analyzers. Notice also that the PR states "Biocurex gained a higher royalty" meaning that a number was put down in the agreement and ABT is ok with it. So what has changed? To me, rather than a return or a face saving deal, this is an agreement out of mutual recognition that the best way to move this forward is to rely on the expertise of Dr. Moro and not that of ABT staff. After all he has been the one solving problems for ABT. In such a case it would be unfair and inappropriate to keep the same terms of the deal. So in exchange for Dr. Moro doing more, BOCX should get higher royalties.
As BOCX investor, I feel much better knowing that BOCX is in control of their own destiny: get the test perfected on the anlyzer and get more in return. After all, who would we rather have working on perfecting the test BOCX or ABT? Now look at this in the light of the recent activity with IMA and the recent ad for new staff and a strategy begins to emerge.
Notice also the other potential upside to this amended agreement: the bar for royalties just got raised! So all and all this is as bad at might seem at first!
ABK
